INTRODUCTION
Human epidermal growth factor receptor-2 (HER2) overexpression resulting from HER2 gene amplification has been shown in 20-30% of human breast cancers and is associated with poor clinical outcome even with systemic chemotherapy.(1) HER2 gene amplification results in the overexpression of HER2 receptor and the activation of HER2 receptor results in the activation of a complex network of signal pathways that mediate enhanced cell proliferation. (2) Better understanding of the mechanism by which HER2 regulates cell signal pathways may help to determine the biologic role of HER2 in the breast cancer.
A series of in vitro studies have indicated that the effects of HER2 on the cell proliferation involve the modulation of G1 cell cycle regulators such as cyclin D1 and p27Kip1 through multiple signaling pathways. (3, 4) SKBR3 cells accumulate in G1 upon down-regulation of HER2 and HER2 controls G1 to S transition via phosphorylation of retinoblastoma protein (pRB). Inactivating phosphorylation of pRB seems to be mediated by the interactions between cyclin D1/E and p27Kip1 proteins in the study. (3) The p27Kip1 was originally discovered as a cyclin-Purpose: Human epidermal growth factor receptor-2 (HER-2)/neu amplification affects the cell proliferation through the modulation of multiple G1 cell cycle regulators in breast tumor cells. We performed this study to investigate whether retinoblastoma protein (pRB) and p27Kip1 were differently expressed according to the HER2 amplification status in human breast cancer. Methods: HER2 amplification was assayed by fluorescence in situ hybridization and the expression of cell cycle regulators were assayed by immunohistochemistry on 153 consecutive invasive breast cancers. The proliferative activity of breast cancer was analyzed according to the HER2 amplification and cell cycle protein expression status. Results: HER2 amplification was observed in 39 (25.5%) of 153 breast cancers. In the HER2 amplified breast cancers, the pRB expression was significantly increased (p=0.011) whereas there was no significant relationship between HER2 amplification and p27Kip1 expression. There was an inverse correlation between pRB expression and Ki-67 labeling index in the HER2 amplified breast cancers (p= 0.036). In contrast, Ki-67 labeling index was significantly decreased as p27Kip1 expression increased in HER2 nonamplified breast cancers (p=0.028). In HER2 non-amplified breast cancers, we could not observe any association between the pRB expression and Ki67 labeling index. Conclusion: The proliferation of the breast cancers was associated with pRB expression in HER2 amplified tumors whereas it was associated with p27Kip1 expression in HER2 non-amplified tumors. The results of the current study indicate that the cell proliferative activity of the breast cancer is under different growth signal pathways according to HER2 amplification status. dependent kinase (cdk) inhibitor induced by extracellular antimitogenic signals. (5, 6) Rapid elimination of p27Kip1 is probably a prerequisite for the activation of cyclin/cdk complex through cell cycle progression. In vitro data indicated that sequestration of p27Kip1 via ternary complex of cyclin D-cdk4/6-p27Kip1 precedes sequential activation of cyclin E-cdk2 complex in G1-S transition of the cell cycle. (7, 8) Overexpression of HER2 increases the turnover of p27Kip1 in HER2 transfected MCF-7 cells whereas inhibition of HER2 increases nuclear levels of p27Kip1 and its association with nuclear cdk2.(4) The p27Kip1 modulation seems to be a part of growth signaling pathway driven by HER2.
In this study, we analyzed the expression profiles of were collected. The representative tumor blocks were selected and transplanted to the tissue array blocks.
TMA block
Recipient blocks were made with purified agar in 3.8× 2.2 frames. Holes with 2 mm in each size were made on the recipient blocks by core needle and agar core was discarded. Donor blocks were prepared after thorough evaluation of H & E slides. Representative cancer portions retrieved from matching donor blocks were transplanted to the recipient blocks using 2 mm core needle.
Recipient blocks were framed in the mold which is used to frame conventional paraffin block, and then paraffin was added to the frame. Three μ m sections were cut from the recipient blocks using an adhesive coated slide system (Instrumedics Inc., Hackensack, USA) supporting the cohesion of the 2 mm array elements on the glass. (9) 2. Fluorescence in situ hybridization (FISH) for HER2 amplification Two-color FISH was done on a 3 μ m-thick consecutive microarray sections. Before hybridization, the sections were deparaffinized, air dried, and dehydrated in 100% ethanol after incubation at 56℃ for 24 hr. Microarray slides were treated in wash buffer (Vysis Inc., Downers Grove, USA) for 3 min after treatment with 0.2N HCl for 20 min. Pretreatment solution (Vysis Inc., Downers Grove, USA) at 80℃ was applied for 30 min and the slides were washed with purified water. Slides were treated were treated with wash buffer twice for 5 min serially.
Immersed slides in Protease solution (Vysis Inc., Downers
Grove, USA) at 37℃ was applied for 10 min and the slides were washed with wash buffer at 45-50℃ and air dried.
Slides were fixed in 10% buffered formalin for 10 min and then washed with wash buffer at 45-50℃. For denaturation, slides were immersed in denaturation solution (Vysis Inc., Downers Grove, USA) for 5 min at 72℃ followed by dehydration with 70%, 85% and 100% ethanol serially at 45-50℃. For hybridization, 20 μ L LSI HER-2/CEP17 probe (PathVision TM , Vysis Inc., Downers Grove, USA) was applied and a coverslip was applied over the probe. After overnight hybridization at 37℃ in a humidified chamber, the slides were washed with 72℃ posthybridization wash buffer (PHWB, Vysis Inc., Downers Grove, USA) for 2 min. Nuclei were counterstained with 20 μ L 4,6-diamino-2-phenylindole (DAPI, Vysis Inc., Downers Grove, USA). The centromere 17 (CEP) and HER2 copy numbers were counted in the predominant tumor cell population.
Hybridization signals were enumerated by the ratio of orange signals for HER2 to green signals for CEP17 in morphologically intact and non-overlapping nuclei. At least two times more HER2 signals than CEP17 signals in the tumor cells were considered as criteria for HER2 amplification.
Immunohistochemistry (IHC)
After deparaffinization and dehydration of the slides, heat induced epitope retrieval was done at 95℃ for 15 min. TMA slides were stained with specific antibodies to HER2 Amplification and Cell Proliferation p27Kip1 and pRB; mouse monoclonal antibody DCS-72. 
Statistics
Results of IHC for molecular markers were merged and analyzed. The chi-square test and Fisher' s exact test were used for data analyses, and the correlation between molecular markers was estimated by Spearman' s correlation coefficient. Calculations were performed with the use of SPSS statistical software, version 11.5. The differences were considered significant when p-values were 0.05.
RESULTS
HER2 amplification was observed in 39 (25.5%) of 153 breast cancers. We analyzed the HER2 amplification according to the various clinical and biologic characteristics of the studied patients. The frequency of HER2 amplification was significantly increased in high grade tumors (p=0.023), but there was no statistically significant association between HER2 amplification and other variables such as the status of estrogen receptor (ER) expression and lymph node metastasis ( Table 1 ).
Association between HER2 amplification and pRB expression, but not with p27Kip1
The expression of p27Kip1 and pRB was assessed on the consecutive sections of TMA blocks. pRB was expressed in 72 tumors (47.1%). pRB was expressed in 45 (39.5%) of 114 tumors without HER2 amplification whereas it was expressed in 27 (69.2%) of 39 tumors with HER2 amplification ( Table 2 ). The frequency of pRB expression
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Change of proliferative index (PI) according to HER2 amplification and expression of pRB and p27Kip1
The PI of the individual tumor was assessed by Ki67 labeling index and the change of PI was analyzed according to the expression of the studied cell cycle regulators. Table 5 ). The PI was significantly decreased in the tumors with p27kip1 expression. The association between pRB expression and PI was not observed in these tumors.
DISCUSSION
pRB was significantly increased in the HER2-amplified tumors in this study, whereas there was no significant association between the HER2 amplification and the ex- 
